medigraphic.com
Academia Mexicana de Neurología, A.C.

2014, Number 1

<< Back Next >>

Rev Mex Neuroci 2014; 15 (1)

Association between mild cognitive impairment and cerebral vasoreactivity documented by transcranial Doppler in subjects older than 60 years

Isordia-Martínez J, Góngora-Rivera F, Villarreal-Garza E, Soto-Valdez A, Espinosa-Ortega M

Language: Spanish
References: 31
Page: 23-30
PDF size: 169.39 Kb.


ABSTRACT

Introduction: Identifying Mild Cognitive Impairment (MCI) allows us to start treatment to delay or modify the course of the dementia syndrome and can find new diagnostic tools and therapeutic monitoring.
Objetive: The aim of this study was to determine the association of demographic, clinical and laboratory alterations in cerebral vasoreactivity measured by transcranial Doppler sonography in the population of subjects aged 60 years and its possible association with the DCL.
Material and Methods: We included patients older than 60 years with no history of neurological disease, terminal illness or significant carotid stenosis (greater than 70 %).
Results: We included 105 patients, 44 (41.9%) men, 61 (58.1%) women with a mean age of 72.8 ± 3.9 years. Among the cardiovascular risk factors frequently include 35 (33.3%) hypertensive, 32 (30.5%) diabetic and 38 (36.2 %) controls. The intimamedia thickness (IMT) averaged 0.63 ± 0.23 mm. Identified 39 (37%) subjects with diminished VRC. The antihypertensive treatment was associated with higher levels of VRC at 5% (p = 0.024). The mean MMSE was 28 (14-30) points with a neuropsychiatric 96 (27-119). We identified 16 cases of DLB (15%), mostly male (75%), and with an average age of 73 (66-82) years. The variables associated with DCL were gender (p = 0.005) BUN (p = 0.041), mean arterial pressure at the end of the CRC test (p = 0.045). In multivariate analysis, gender and BUN remained associated with the presence of MCI (p = 0.033, p = 0.014). The DCL is not significantly associated with changes in cerebral vasoreactivity. The prevalence of MCI in our population is 15%.
Conclusion: This study is part of a prospective cohort study that aims to demonstrate that changes in HRV may be associated with the onset of neurocognitive changes after 5 years of follow up and let questioned about the effect of antihypertensive treatment and its possible effect on cerebral vasoreactivity.


REFERENCES

  1. Gauthier S, Reisberg B, Zaudig M, Petersen RC, Ritchie K, Broich K, et al. International Psychogeriatric Association Expert Conference on mild cognitive impairment. Mild cognitive impairment. Lancet 2006; 367: 1262-70.

  2. Panza F, D’Introno A, Colacicco AM, Capurso C, Del Parigi A, Caselli RJ, et al. Current epidemiology of mild cognitive impairment and other predementia syndromes. Am J Geriatr Psychiatry 2005; 13: 633-44.

  3. Mejía-Arango S, Miguel-Jaimes A, Villa A, Ruiz-Arregui L, Gutiérrez- Robledo LM. Deterioro cognoscitivo y factores asociados en adultos mayores en México. Salud Publica Mex 2007; 49: s475-s481.

  4. Leys D, Hénon H, Mackowiak-Cordoliani M-A, Pasquier F. Poststroke dementia. Lancet Neurol 2005; 4: 752-9.

  5. Pinto C, Subramanyam AA. Mild cognitive impairment: The dilemma. Indian J Psychiatry 2009; 51(Suppl. 1): S44-51.

  6. Asil T, Uzuner N. Differentiation of vascular dementia and Alzheimer disease: a functional transcranial Doppler ultrasonographic study. J Ultrasound Med 2005; 24:1065-70.

  7. Venkataraman K, Khurana S, Tai TC. Oxidative stress in aging-matters of the heart and mind. Int J Mol Sci 2013; 14: 17897-925.

  8. Kumar P, Dezso Z, MacKenzie C, Oestreicher J, Agoulnik S, Byrne M, et al. Circulating miRNA biomarkers for Alzheimer’s disease. PLoS One 2013; 8: e69807.

  9. Lazarczyk MJ, Hof PR, Bouras C, Giannakopoulos P. Preclinical Alzheimer disease: identification of cases at risk among cognitively intact older individuals. BMC Med 2012; 10: 127.

  10. Cervantes-Arriaga A, Calleja-Castillo J, Rodríguez-Violante M. Función cognitiva y factores cardiometabólicos en diabetes mellitus tipo 2. Med Interna Mex 2009; 25: 386-92.

  11. Roriz-Filho J, Sá-Roriz TM, Rosset I, Camozzato AL, Santos AC, Chaves ML, et al. (Pre)diabetes, brain aging, and cognition. Biochim Biophys Acta 2009; 1792: 432-43.

  12. Taylor VH, MacQueen GM. Cognitive dysfunction associated with metabolic syndrome. Obes Rev 2007; 8: 409-18.

  13. Aguilar-Salinas CA, Gómez-Pérez FJ, Rull J, Villalpando S, Barquera S, Rojas R. Prevalence of dyslipidemias in the Mexican National Health and Nutrition Survey 2006. Salud Publica Mex 2010; 52(Suppl. 1): S44-53.

  14. Puddu P, Puddu GM, Zaca F, Muscari A. Endothelial dysfunction in hypertension. Acta Cardiol 2000; 55: 221-32.

  15. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281-357.

  16. Cigada M, Marzorati S, Tredici S, Iapichino G. Cerebral CO2 vasoreactivity evaluation by transcranial Doppler ultrasound technique: a standardized methodology. Intensive Care Med 2000; 26: 729-32.

  17. Baumbach GL, Heistad DD. Cerebral circulation in chronic arterial hypertension. Hypertension 1988; 12: 89-95.

  18. Troisi E, Attanasio A, Matteis M, Bragoni M, Monaldo BC, Caltagirone C, et al. Cerebral hemodynamics in young hypertensive subjects and effects of atenolol treatment. J Neurol Sci 1998; 159: 115-9.

  19. Curb JD, Abbott RD, MacLean CJ, Rodriguez BL, Burchfiel CM, Sharp DS, et al. Age-related changes in stroke risk in men with hypertension and normal blood pressure. Stroke 1996; 27: 819-24.

  20. Tominaga S, Strandgaard S, Uemura K, Ito K, Kutsuzawa T. Cerebrovascular CO2 reactivity in normotensive and hypertensive man. Stroke1976; 7: 507-10.

  21. Strandgaard S, Olesen J, Skinhoj E, Lassen NA. Autoregulation of brain circulation in severe arterial hypertension. Br Med J 1973; 1: 507-10.

  22. Malatino LS, Bellofiore S, Costa MP, Lo Manto G, Finocchiaro F, Di Maria GU. Cerebral blood flow velocity after hyperventilation-induced vasoconstriction in hypertensive patients. Stroke1992; 23: 1728-32.

  23. Ferrara LA, Mancini M, Iannuzzi R, Marotta T, Gaeta I, Pasanisi F, et al. Carotid diameter and blood flow velocities in cerebral circulation in hypertensive patients. Stroke 1995; 26: 418-21.

  24. Lemne C, Jogestrand T, de Faire U. Carotid intima-media thickness and plaque in borderline hypertension. Stroke 1995; 26: 34-9.

  25. Rojas-Martínez R, Aguilar-Salinas CA, Jiménez-Corona A, Gómez-Pérez FJ, Barquera S, Lazcano-Ponce E. Prevalence of obesity and metabolic syndrome components in Mexican adults without type 2 diabetes or hypertension. Salud Publica Mex 2012; 54: 7-12.

  26. Heliopoulos I, Artemis D, Vadikolias K, Tripsianis G, Piperidou C, Tsivgoulis G. Association of ultrasonographic parameters with subclinical white-matter hyperintensities in hypertensive patients. Cardiovasc. Psychiatry Neurol 2012; 2012: 616572.

  27. Arredondo A, Zuñiga A. Epidemiological changes and financial consequences of hypertension in Latin America: implications for the Isordia-Martínez Javier, et al. Deterioro cognitivo leve y vasorreactividad cerebral 30 Rev Mex Neuroci Enero-Febrero, 2014; 15(1): 23-30 health system and patients in Mexico. Cad Saude Publica 2012; 28: 497-502.

  28. Hajjar I, Hart M, Chen Y-L, Mack W, Novak V, C Chui H, et al. Antihypertensive therapy and cerebral hemodynamics in executive mild cognitive impairment: results of a pilot randomized clinical trial. J Am Geriatr Soc 2013; 61: 194-201.

  29. Kuriyama Y, Hashimoto H, Nagatsuka K, Sawada T, Omae T. Effects of dihydropyridines on cerebral blood vessels. J Hypertens 1993; 11: S9-12.

  30. Kuriyama Y, Nakamura M, Kyougoku I, Sawada T. Effects of carvedilol on cerebral blood flow and its autoregulation in previous stroke patients with hypertension. Eur J Clin Pharmacol 1990; 38(Suppl. 2): S120-1.

  31. Forteza A, Romano JG, Campo-Bustillo I, Campo N, Haussen DC, Gutierrez J, et al. High-dose atorvastatin enhances impaired cerebral vasomotor reactivity. J Stroke Cerebrovasc Dis 2012; 21: 487-92.




2020     |     www.medigraphic.com